Clinical trials: Carcinoma, Small Cell
Extensive-stage Small-cell Lung Cancer
To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.
- Trial name
- SCLC (NCT04894591)
- Testing
- Zepzelca
- Where
- 41 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- Jazz Pharmaceuticals
Cancer, Tumor, Solid
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
This is a phase 1/2, open-label, multi-center, first-in-human, two-stage (Part 1: dose escalation and Part 2: dose expansion) study evaluating multiple doses and schedules of intravenously (IV) administered HMBD-002, with or…
- Conditions
- Cancer, Tumor, Solid, Nonsmall Cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05082610
- Testing
- HMBD-002, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Hummingbird Bioscience
Non-Small-Cell Lung Carcinoma
Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients
Primary : To determine the safety profile of each treatment group. Secondary : To determine efficacy in term of overall response, disease free survival and survival at 1 and 2 years.
- Trial name
- NCT00271323
- Testing
- docetaxel and cisplatin, radiotherapy
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Sanofi
Non-Small Cell Lung Cancer, Pancreatic Cancer
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
This is a clinical trial examining the safety, pharmacokinetics, pharmacodynamics and efficacy of IV NPI-0052 (a proteasome inhibitor) in combination with oral vorinostat (Zolinza; a HDAC inhibitor) in patients with non-small…
- Conditions
- Non-Small Cell Lung Cancer, Pancreatic Cancer, Melanoma, Lymphoma
- Trial name
- NCT00667082
- Testing
- NPI-0052 (marizomib) + vorinostat
- Where
- 3 sites in Australia
- Volunteers
- 22 people
- Sponsor
- Celgene
Non-Small Cell Lung Cancer
A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
To assess the efficacy and safety of sunvozertinib versus placebo as adjuvant therapy in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations…
- Trial name
- NCT07182682
- Testing
- sunvozertinib
- Where
- 49 sites in China
- Volunteers
- 360 people
- Sponsor
- Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Advanced Solid Tumors
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-155 alone and in combination with paclitaxel or docetaxel.
- Trial name
- NCT03595059
- Testing
- ABBV-155, Paclitaxel, Docetaxel
- Where
- 40 sites in United States, Australia and 8 more
- Volunteers
- 168 people
- Sponsor
- AbbVie
Non-Small Cell Lung Cancer
Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients
The primary objective of this study is to characterize the safety profile of sotorasib.
- Trial name
- NCT07143513
- Testing
- Sotorasib
- Where
- 3 sites in China
- Volunteers
- 102 people
- Sponsor
- Amgen
Lung Neoplasms, Carcinoma
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer
The purpose of the study is to determine if U.S. manufactured Cetuximab can be safely used for the treatment of Non-Small Cell Lung Cancer in combination with Cisplatin and Vinorelbine.
- Conditions
- Lung Neoplasms, Carcinoma, Cancer of the Lung, Non-Small-Cell Lung Carcinoma
- Trial name
- NCT01109524
- Testing
- Cetuximab, Cisplatin, Vinorelbine
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
NSCLC, Stage III
A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
This is a phase II trial assessing the efficacy and safety of GFH018 and Toripalimab in combination with concurrent chemoradiotherapy (cCRT) in patients with unresectable, locally advanced, Stage III non-small cell lung cancer…
- Trial name
- NCT05386888
- Testing
- GFH018, Toripalimab, Paclitaxel
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Non Small Cell Lung Carcinoma, Metastatic Breast Cancer
Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)
The purpose of this non-interventional study is to collect data on efficacy and toxicity of the use of Navelbine ORAL in daily routine in Germany (especially after availability of an 80mg capsule).
- Trial name
- NCT00890903
- Where
- Germany
- Volunteers
- 62 people
- Sponsor
- Pierre Fabre Pharma GmbH
Non-Small Cell Lung Cancer
Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)
The purpose of the study is to determine patient characteristics from patients that have used Iressa for a period of minimal 3 years.
- Trial name
- NCT01103089
- Where
- 11 sites in Netherlands
- Volunteers
- 10 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients
The main objective of this study is to evaluate the safety and tolerability of BPI-15086.
- Trial name
- NCT02914990
- Testing
- BPI-15086
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer
Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy
This active surveillance aims to collect the safety data of 100 NSCLC patients treated with nintedanib per the approved Indian label within 2 years from the date of commercial availability of the drug in India (23rd January…
- Trial name
- NCT03017885
- Where
- 11 sites in India
- Volunteers
- 28 people
- Sponsor
- Boehringer Ingelheim
Non-Small Cell Lung Cancer
Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC
This is an open-label, dose-escalation Phase I study to evaluate the safety and tolerability of RX001 monotherapy in patients with advanced KRAS mutant NSCLC.
- Trial name
- NCT06934590
- Testing
- RX001
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- GeneCraft Inc.
Carcinoma, Non-Small-Cell Lung
Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC
The trial objective will be to evaluate whether BI 6727 monotherapy or in combination with pemetrexed may be effective in the treatment of advanced or metastatic NSCLC in patients who relapsed after or failed first-line platinum…
- Trial name
- NCT00824408
- Testing
- pemetrexed, BI 6727
- Where
- 12 sites in Canada, The Bahamas
- Volunteers
- 143 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer
Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and…
- Trial name
- NCT03910127
- Testing
- TQB2450, Anlotinib
- Where
- 3 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)
The purpose of this study is to demonstrate improvement in overall survival for the combination of whole brain radiation therapy (WBRT) plus temozolomide (TMZ) versus WBRT alone.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Brain Neoplasms
- Trial name
- NCT00076856
- Testing
- Temozolomide
- Volunteers
- 95 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to compare combination treatment of gemcitabine + oxaliplatin (GEMOX) with carboplatin + paclitaxel (CP) to determine if there is a difference in response and safety between the two drug combinations…
- Trial name
- NCT00087802
- Testing
- gemcitabine/Eloxatin (GEMOX), carboplatin/paclitaxel (CP)
- Where
- 70 sites in United States
- Volunteers
- 383 people
- Sponsor
- Sanofi
Carcinoma, Non-Small-Cell Lung
Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
The purpose of this study is to determine the best confirmed response rate of daily administration of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR and VEGFR2) XL647 in subjects with NSCLC who have…
- Trial name
- NCT00522145
- Testing
- XL647
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Kadmon Corporation, LLC
NSCLC Stage IV
Study of AGEN1884 With Pembrolizumab in 1L NSCLC
A Phase IIa Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination with Pembrolizumab in Subjects with Chemotherapy Naïve, PD-L1 high, metastatic…
- Trial name
- NCT03411473
- Testing
- AGEN1884 in combination with pembrolizumab
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 2 people
- Sponsor
- Agenus Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.